XML 37 R25.htm IDEA: XBRL DOCUMENT v3.21.1
Collaboration and Other Agreements - Incyte Corporation (Details)
1 Months Ended 3 Months Ended 39 Months Ended
Oct. 31, 2017
USD ($)
performanceObligation
Mar. 31, 2021
USD ($)
Mar. 31, 2020
USD ($)
Dec. 31, 2017
USD ($)
Mar. 31, 2021
USD ($)
Collaboration And Other Agreements [Line Items]          
Revenues   $ 16,881,000 $ 13,682,000    
Incyte Corporation | Incyte MGA012 Agreement          
Collaboration And Other Agreements [Line Items]          
Non-refundable upfront payment       $ 150,000,000.0  
Potential development and regulatory milestone payments under agreement $ 420,000,000.0        
Potential commercial milestone payments under agreement $ 330,000,000.0        
Development and regulatory milestones recognized   10,000,000.0     $ 65,000,000.0
Number of performance obligations | performanceObligation 2        
Collaborative agreement transaction price $ 154,000,000.0        
Variable consideration recognized $ 4,000,000.0        
Maximum | Incyte Corporation | Incyte MGA012 Agreement          
Collaboration And Other Agreements [Line Items]          
Potential proceeds from royalties (percent) 24.00%        
Minimum | Incyte Corporation | Incyte MGA012 Agreement          
Collaboration And Other Agreements [Line Items]          
Potential proceeds from royalties (percent) 15.00%        
Revenues From License Agreements | Incyte Corporation | Incyte MGA012 Agreement          
Collaboration And Other Agreements [Line Items]          
Revenues $ 150,000,000.0        
Revenues From License Agreements | Incyte Corporation | Incyte MGA012 Agreement - Clinical activities          
Collaboration And Other Agreements [Line Items]          
Revenues     0    
Revenues From License Agreements | Incyte Corporation | Incyte MGA012 Clinical Services          
Collaboration And Other Agreements [Line Items]          
Revenues   100,000 $ 5,900,000    
Revenues From License Agreements | Incyte Corporation | Incyte MGA012 Supply Agreement          
Collaboration And Other Agreements [Line Items]          
Revenues   $ 3,100,000